Osteoporosis, Postmenopausal — Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
Citation(s)
A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal)